Literature DB >> 8670595

Polymyalgia rheumatica is associated with both HLA-DRB1*0401 and DRB1*0404.

S Haworth1, J Ridgeway, I Stewart, P A Dyer, L Pepper, W Ollier.   

Abstract

The frequency of HLA-DRB1 alleles was determined in 68 Caucasoid patients with polymyalgia rheumatica (PMR) and 140 controls using polymerase chain reaction (PCR) sequence-specific oligonucleotide typing. In keeping with previous studies, an increased frequency of DRB1*04 was observed in patients [55.9% vs 35.0%, odds ratio (OR) 2.4, 95% confidence interval (CI) 1.3-4.4]. HLA-DRB1*0101 frequency was also increased in patients, although less confidence could be placed on this association (19.1% vs 14.3%, OR 1.4, 95% CI 0.6-3.3). HLA-DRB1*04 subtyping indicated that the frequencies of both DRB1*0401 (38.2% vs 22.1%, OR 2.2, 95% CI 1.0-4.3) and DRB1*0404 (16.2% vs 5.0%, OR 3.7, 95% CI 1.2-11.1) were specifically raised. An increased frequency of the RA shared epitope (QKRAA/QRRAA) was also observed in this group (75.0% vs 44.2%, OR 3.8, 95% CI 1.9-7.6). When the analysis was restricted to only DRB1*04-negative patients and controls, the frequencies of DRB1*0301, *11 and *08 were marginally raised. However, no obvious relationship appeared to exist between PMR susceptibility and DRB1 alleles carrying the DYF conserved epitope in the second hypervariable region. Autoantibodies to thyroid antigens were present in 23% of patients. An increased frequency of DRB1*0301 was observed in patients with thyroid microsomal antibodies compared to those without (54.5% vs 24.6%, OR 3.7, 95% CI 0.8-17.0). This increase was not observed in patients with thyroglobulin autoantibodies. These data indicate that both DRB1*0401 and *0404 are associated with PMR, and that this may extend to include DRB1*0101. The immunogenetic profile of susceptibility markers in this condition appears to be similar to that in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8670595     DOI: 10.1093/rheumatology/35.7.632

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  8 in total

1.  HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity.

Authors:  C Salvarani; L Boiardi; V Mantovani; A Ranzi; F Cantini; I Olivieri; M Bragliani; E Collina; P Macchioni
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  Genetic and environmental factors in polymyalgia rheumatica.

Authors:  M A Cimmino
Journal:  Ann Rheum Dis       Date:  1997-10       Impact factor: 19.103

Review 3.  Giant cell arteritis with ocular complications discovered simultaneously in two sisters.

Authors:  F Gros; J F Maillefert; A Behin; F Guignier; C Piroth; C Creuzot-Garcher; C Tavernier
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Polymyalgia Rheumatica Following COVID-19 Vaccination.

Authors:  Akira Yokote; Shinsuke Fujioka; Nobutaka Takahashi; Takayasu Mishima; Yoshio Tsuboi
Journal:  Intern Med       Date:  2022-03-26       Impact factor: 1.282

Review 5.  Epidemiology and optimal management of polymyalgia rheumatica.

Authors:  P Labbe; P Hardouin
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 4.271

6.  Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank.

Authors:  Adrian Cortes; Calliope A Dendrou; Allan Motyer; Luke Jostins; Damjan Vukcevic; Alexander Dilthey; Peter Donnelly; Stephen Leslie; Lars Fugger; Gil McVean
Journal:  Nat Genet       Date:  2017-07-31       Impact factor: 38.330

7.  HLA-DRB1 allelic epitopes that associate with autoimmune disease risk or protection activate reciprocal macrophage polarization.

Authors:  Vincent van Drongelen; Bruna Miglioranza Scavuzzi; Sarah Veloso Nogueira; Frederick W Miller; Amr H Sawalha; Joseph Holoshitz
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

Review 8.  The Immunopathology of Giant Cell Arteritis Across Disease Spectra.

Authors:  Michelle L Robinette; Deepak A Rao; Paul A Monach
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.